September 15, 2008

U.S. District Court in Delaware Reinstates Damage Awards to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation

MIAMI, Sept 15, 2008 /PRNewswire via COMTEX News Network/ -- The U.S. District Court in Delaware today granted Cordis Corporation's motion for final judgment against Boston Scientific Corporation and Medtronic, Inc. in their cases involving the original Palmaz balloon expandable stent patent.

Cordis had asked U.S. District Court Judge Sue Robinson to reinstate the damages verdicts Cordis had obtained in 2000, plus accrued interest. In its order, the Court indicated its intention to enter final judgment on September 30, 2008, including an award of pre-judgment interest at the prime rate.

"We are very pleased that Judge Robinson granted our motion for reinstatement of damages and gratified that this litigation finally appears to be drawing to a close," said Seth Fischer, Company Group Chairman for the Cordis franchise.

Both patent infringement cases were originally tried in 2000, with Cordis receiving favorable jury verdicts at that time of $324 million against Boston Scientific and $271 million against Medtronic, prior to the addition of interest. After a series of procedural rulings and appeals, both cases were retried in March of 2005, with Cordis prevailing again.

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.

SOURCE Cordis Corporation

http://www.cordis.com

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX


Close window | Back to top

Copyright 2013 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.